Borstkanker Onderzoek Groep — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Borstkanker Onderzoek Groep appears in 24 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials24

Recruiting shown3

Roles2

SourceClinicalTrials.gov

Clinical trials

24 shown

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)NCT05392608 · lead sponsor · 2022-06-02

ACTIVE_NOT_RECRUITING

TAS102 in Patients With ER-positive, HER2-negative Advanced Breast CancerNCT04489173 · lead sponsor · 2020-09-25

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.NCT03283384 · lead sponsor · 2019-06-15

ACTIVE_NOT_RECRUITING

Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 StudyNCT03820063 · lead sponsor · 2019-02-27

ACTIVE_NOT_RECRUITING

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast CancerNCT03532087 · lead sponsor · 2018-02-01

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerNCT03425838 · lead sponsor · 2017-11-09

ACTIVE_NOT_RECRUITING

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast CancerNCT01935492 · lead sponsor · 2010-11-01

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer PatientsNCT01099436 · lead sponsor · 2010-04-01

Postoperative Re-irradiaTion With and Without HYPERthermia, or Surgery Only: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast CancerNCT06452485 · collaborator · 2024-02-01

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · collaborator · 2023-12-15

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic TherapyNCT05416164 · collaborator · 2022-10-07

Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side EffectsNCT06424054 · collaborator · 2025-06-01

NOT_YET_RECRUITING

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast CancerNCT05503108 · collaborator · 2023-03-17

Effectiveness of Personalized Surveillance and Aftercare for Breast CancerNCT05975437 · collaborator · 2023-03-06

ENROLLING_BY_INVITATION

Management of Low-risk (Grade I and II) DCISNCT02492607 · collaborator · 2017-02-13

ACTIVE_NOT_RECRUITING

Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving TherapyNCT02271828 · collaborator · 2015-05-18

Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a MastectomyNCT02112682 · collaborator · 2014-06-01

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneNCT02109913 · collaborator · 2014-03-01

DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast CancerNCT02126449 · collaborator · 2014-02-01

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2NCT01996267 · collaborator · 2013-12-01

ACTIVE_NOT_RECRUITING

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerNCT01898117 · collaborator · 2013-07-01

ACTIVE_NOT_RECRUITING

Systemic Therapy With or Without Upfront Surgery in Metastatic Breast CancerNCT01392586 · collaborator · 2012-02-01

Male Breast Cancer: Understanding the Biology for Improved Patient CareNCT01101425 · collaborator · 2010-12-01

ACTIVE_NOT_RECRUITING

Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the BreastNCT00470236 · collaborator · 2007-06-01

Drugs studied in this sponsor's trials

12 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Borstkanker Onderzoek Groep as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

fulvestrant2

alpelisib 150 MG Oral Tablet [Piqray]1

cyclophosphamide1

docetaxel1

doxorubicin hydrochloride1

elacestrant1

exemestane 25 MG1

letrozole1

fulvestrant RxCUI 282357 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials alpelisib 150 MG Oral Tablet [Piqray] RxCUI 2169307 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cyclophosphamide RxCUI 3002 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial doxorubicin hydrochloride RxCUI 142433 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial elacestrant RxCUI 2628469 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial exemestane 25 MG RxCUI 330333 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial letrozole RxCUI 72965 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel RxCUI 56946 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial tamoxifen RxCUI 10324 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial tipiracil / trifluridine RxCUI 1670310 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial zoledronic acid RxCUI 77655 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator16

lead sponsor8

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.